| Project/Area Number |
15K09235
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
Oka Mikio 川崎医科大学, 医学部, 教授 (40223995)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肺がん / がん精巣抗原 / がん免疫 / がん免疫療法 / 予後因子 / 免疫チェックポイント / 抗体療法 / 個別化医療 / がん免疫応答 / バイオマーカー / 腫瘍免疫 / がん抗原 / 肺腺がん / 免疫モニタリング |
|---|
| Outline of Final Research Achievements |
Firstly, relationship between immune-related molecules and prognosis was investigated in 120 lung adenocarcinoma tissues, resulted in independent poor prognostic factors of XAGE1 expression and negative T-cell infiltration. Then, the formula predicting their prognosis was created by cluster classification using tumor PD-L1, galectin-9, and XAGE1 antigen expression, and T-cell infiltration, and it almost accurately predicted their prognosis.
Secondly, we found that XAGE1 antigen was expressed in approximately 50% of lung adenocarcinomas and that it’s antibody was detected in almost half of those with XAGE1 antigen. As one reason for negative XAGE1antibody in lung adenocarcinomas with XAGE1 antigen, regulatory T-cell and B-cell infiltrate into tumor site.
Thirdly, we found a bio marker predicting response to immunotherapy in non-small cell lung cancer and applied the patent (#2017-094986) in Japan, however; the biomarker cannot be open here because of submitting its paper.
|
